
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CYTK | NASDAQ | USD | Real-time | |
1CYTK | Milan | EUR | Real-time | |
KK3A | TradeGate | EUR | Delayed |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
James H. Sabry | 64 | 1997 | Co-Founder & Chairman of Scientific Advisory Board |
Lawrence S. B. Goldstein | - | - | Member of Scientific Advisory Board |
Thomas D. Pollard | - | - | Member of Scientific Advisory Board |
David J. Morgans | 69 | 2006 | Member of Scientific Advisory Board |
Wendell D. Wierenga | 76 | 2011 | Independent Director |
John Tannahill Henderson | 78 | 2009 | Independent Chairman |
John Lowe | - | - | Member of Scientific Advisory Board |
Brian M. Stoltz | - | - | Member of Scientific Advisory Board |
Paul A. Wender | - | - | Member of Scientific Advisory Board |
John Solaro | - | - | Member of Scientific Advisory Board |
Robert I. Blum | 60 | 2004 | CEO, President & Director |
H. Lee Sweeney | - | - | Member of Scientific Advisory Board |
Edward M. Kaye | 75 | 2016 | Independent Director |
David A. Kass | - | - | Member of Scientific Advisory Board |
Roger A. Fielding | - | - | Member of Scientific Advisory Board |
B. Lynne Parshall | 70 | 2013 | Independent Director |
Nancy J. Wysenski | 66 | 2020 | Independent Director |
Muna Bhanji | 61 | 2021 | Independent Director |
Robert A. Harrington | 63 | 2022 | Independent Director |
James A. Spudich | 83 | 1997 | Co-Founder & Member of Scientific Advisory Board |
Robert E. Landry | 61 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review